Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
ETHINYLESTRADIOL ; ETONOGESTREL
Actavis Group PTC ehf
G02BB01
ETHINYL ESTRADIOL ; ETONOGESTREL
Hulpmiddel voor vaginaal gebruik
COPOLYMEER VAN ETHYLEEN-VINYLACETAAT (28 pCt. vinylacetaat) ; COPOLYMEER VAN ETHYLEEN-VINYLACETAAT (9 pCt. vinylacetaat) ; MAGNESIUMSTEARAAT (E 470b)
Vaginaal gebruik
Vaginal Ring With Progestogen And Estrogen
2019-04-02
1 PACKAGE LEAFLET: INFORMATION FOR THE USER Perlinring 0,120 mg/0,015 mg per 24 uur, hulpmiddel voor vaginaal gebruikIMPORTANT THINGS TO KNOW ABOUT COMBINED HORMONAL CONTRACEPTIVES (CHCS): - They are one of the most reliable reversible methods of contraception if used correctly. - They slightly increase the risk of having a blood clot in the veins and arteries, especially in the first year or when restarting a combined hormonal contraceptive following a break of 4 or more weeks. - Please be alert and see your doctor if you think you may have symptoms of a blood clot (see section 2 “Blood clots”). READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What /…/ is and what it is used for 2. What you need to know before you use /…/ 3. How to use /…/ 4. Possible side effects 5. How to store /…/ 6. Contents of the pack and other information 1. WHAT /…/ IS AND WHAT IT IS USED FOR /.../ is a contraceptive vaginal ring used to prevent pregnancy. Each ring contains a small amount of two female sex hormones – etonogestrel and ethinylestradiol. The ring slowly releases these hormones into the blood circulation. Because of the low amount of hormones that is released, /.../ is considered a low-dose hormonal contraceptive. Since /.../ releases two different types of hormones it is a so-called combined hormonal contraceptive. /.../ works just like a combined contraceptive pill (the Pill) but instead of taking a pill every day, the ring is used for 3 weeks in a row. /.../ releases two female sex hormones that prevent the release Lees het volledige document
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Perlinring 0,120 mg/0,015 mg per 24 uur, hulpmiddel voor vaginaal gebruik 2. QUALITATIVE AND QUANTITATIVE COMPOSITION /.../ contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. The ring releases etonogestrel and ethinylestradiol at an average amount of 120 micrograms and 15 micrograms respectively per 24 hours, over a period of 3 weeks. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Vaginal delivery system. /.../ is flexible, transparent, and colourless to almost colourless ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Contraception. /.../ is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The decision to prescribe /.../ should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with /.../ compares with other CHCs (see sections 4.3 and 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology To achieve contraceptive effectiveness, /.../ must be used as directed (see 'How to use /.../' and 'How to start /.../'). _Paediatric population _ The safety and efficacy of /.../ in adolescents under the age of 18 years have not been established. Method of administration HOW TO USE /.../ The woman herself can insert /.../ in the vagina. The physician should advise the woman how to insert and remove /.../. For insertion the woman should choose a position that is most comfortable for her, e.g. standing with one leg up, squatting, or lying down. /.../ should be compressed and inserted into the 2 vagina until it feels comfortable. The exact position of /.../ in the vagina is not critical for the contraceptive effect of the ring (see Figures 1-4). Once /.../ has been inserted (see 'How to start /.../') it is left in the vagina continuously for 3 weeks. Advise women to regularly check for the p Lees het volledige document